March 2026 in “American Journal of Clinical Dermatology” Dermatologists should respect Muslim patients' cultural and religious practices for better care.
February 2026 in “BMC Plastic and Reconstructive Surgery” Induced pluripotent stem cells could improve chronic wound healing but face safety and effectiveness challenges.
February 2026 in “Scientific Reports” The gel is safe and effective for treating oral mucositis from chemotherapy and radiation.
The treatment showed limited success in repigmenting hair for vitiligo-associated leukotrichia.
January 2026 in “Nature Communications” A wearable device using NIR light may help treat hair loss non-invasively.
January 2026 in “Food and Feed Research” Bananas have many health benefits, including treating diarrhea, diabetes, and colds.
January 2026 in “Clinical Cosmetic and Investigational Dermatology” Placenta polypeptide injection is a safe and effective treatment for sensitive skin.
December 2025 in “MEDFARM Jurnal Farmasi dan Kesehatan” Topical metformin shows promise for treating skin conditions like acne and psoriasis.
December 2025 in “Cosmoderma” Systemic corticosteroids help manage vitiligo by slowing progression and aiding repigmentation.
December 2025 in “International Journal of Pharmacology” iPSC-derived artificial platelets show promise for consistent and effective regenerative therapies.
November 2025 in “Molecular and Cellular Biomedical Sciences” Exosome therapy from treated stem cells may help reduce inflammation and promote hair regrowth in alopecia.
November 2025 in “Frontiers in Endocrinology” Apigenin and ellagic acid may help manage PCOS symptoms.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.
September 2025 in “Archives of Dermatological Research” Basal cell carcinoma is more common than squamous cell carcinoma on the scalp, especially along the part line.
Exosome therapy could help hair growth but needs more research for safety and effectiveness.
February 2025 in “Theranostics” 3D bioprinting with special hydrogels can create artificial skin that heals wounds and regrows hair in mice.
Polarized microscopy helps identify hair irregularities in genetic disorders.
January 2025 in “EXPERIMENTAL ANIMALS” Stingless bee propolis may help regenerate hair follicles and improve pigment function in chemotherapy-induced hair loss.
October 2024 in “Irish Journal of Medical Science (1971 -)” Electrical stimulation with a low-calorie diet reduces appetite, weight, and blood pressure in obese people with sleep apnea.
Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.
May 2024 in “Scientific Reports” Androgen receptors in the mouse brain may explain cognitive and mood changes in prostate cancer treatment.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
December 2023 in “Journal of nutritional science and vitaminology” A zinc-deficient diet stunted growth and affected organs in mice, with C57BL/6J mice showing more severe symptoms.
Plasma gel and PRP treatments improve skin and hair with minimal side effects.
June 2023 in “SPIRE - Sciences Po Institutional REpository” Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.
February 2023 in “International Journal of Medical Arts” Trichloroacetic acid is a safe and effective treatment for hair loss in alopecia areata patients.
November 2022 in “Research Square (Research Square)” Using facial sunscreen and moisturizer may increase the risk of frontal fibrosing alopecia.
September 2022 in “Skin appendage disorders” Seborrheic dermatitis may contribute to the development of central centrifugal cicatricial alopecia.
May 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Primary cilia affect the size and oil production of eye glands but not the oil's makeup.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.